By Counterforce Health Team in Kanuma (sebelipase alfa) —

How to Get Kanuma (Sebelipase Alfa) Covered by Humana in Illinois: Medical Necessity Criteria and Appeals Process

Answer Box: Getting Kanuma Covered by Humana in Illinois

Humana requires prior authorization for Kanuma (sebelipase alfa) with strict medical necessity criteria. You need confirmed LAL deficiency diagnosis (enzyme activity test or LIPA gene variants), clinical evidence of disease (elevated liver enzymes, dyslipidemia), and specialist involvement. First step: Have your metabolic specialist submit a detailed prior authorization request with all diagnostic proof and clinical documentation. If denied, you have 65 days to appeal through Humana's internal process, then can escalate to independent review. Illinois residents have additional external review rights through the state insurance department.

Table of Contents

  1. Humana's LAL-D Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Prior Authorization Process
  4. Common Denial Reasons & Solutions
  5. Appeals Process in Illinois
  6. Required Documentation Checklist
  7. Cost Considerations
  8. When to Escalate
  9. FAQ

Humana's LAL-D Coverage Policy Overview

Humana Medicare Advantage plans cover Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency (LAL-D) only with prior authorization and strict medical necessity criteria. The drug appears on Humana's Medication Preauthorization List for Medicare Advantage and Dual Special Needs Plans, with an active pharmacy coverage policy that requires specific utilization management criteria.

Plan Types Affected

  • Medicare Advantage plans: All require PA through standard Medicare drug benefit
  • Dual Special Needs Plans: Follow same PA requirements with potential Medicaid coordination
  • Part B vs. Part D billing: Kanuma may be covered under medical benefit (Part B) for infusion center administration or pharmacy benefit (Part D) through specialty pharmacy
Note: Coverage can vary by specific plan design. Check your Evidence of Coverage document for your exact plan details.

Medical Necessity Requirements

Humana requires all of the following criteria for Kanuma coverage:

Diagnostic Confirmation

  • Definitive LAL-D diagnosis documented by:
    • Decreased LAL enzyme activity on validated assay (dried blood spot preferred), OR
    • Genetic testing showing pathogenic/likely pathogenic LIPA gene variants

Clinical Evidence of Disease

  • Elevated liver enzymes (ALT/AST) and/or hepatomegaly
  • Dyslipidemia consistent with LAL-D (elevated LDL-C, low HDL-C)
  • In infants: failure to thrive, growth failure, or severe malabsorption

Treatment Justification

  • No appropriate alternative therapy (Kanuma is the only FDA-approved treatment for LAL-D)
  • Specialist involvement (metabolic/genetic specialist, hepatologist, or lipid specialist)
  • Appropriate dosing per FDA labeling:
    • Infants: 1 mg/kg weekly (escalate to 3-5 mg/kg for suboptimal response)
    • Children/adults: 1 mg/kg every other week (escalate to 3 mg/kg for suboptimal response)

Prior Authorization Process

Step-by-Step Approval Process

  1. Gather diagnostic proof (LAL enzyme results and/or genetic testing)
  2. Document clinical manifestations (liver enzymes, lipid profile, imaging)
  3. Obtain specialist recommendation with detailed medical necessity letter
  4. Submit PA request using Humana's Medicare Medication PA form
  5. Coordinate with specialty pharmacy for drug distribution and infusion scheduling

Timelines

  • Standard PA decision: Within 72 hours of complete submission
  • Expedited review: Within 24 hours when delay could seriously jeopardize health
  • Member filing deadline: 65 days from denial notice for appeals
Tip: Request expedited review for infantile-onset LAL-D or rapidly progressive disease by documenting urgent medical need.

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
Insufficient diagnostic proof Submit complete enzyme/genetic testing LAL activity assay results, LIPA sequencing report
Lack of clinical evidence Document disease manifestations Recent labs (ALT/AST, lipids), imaging, growth charts
Inappropriate dosing Align with FDA labeling Weight-based calculation, specialist dosing rationale
Missing specialist involvement Get metabolic/genetic specialist letter Detailed medical necessity from appropriate specialist
Step therapy requirement Request waiver (no alternatives exist) Statement that Kanuma is only FDA-approved LAL-D treatment

Medical Necessity Letter Essentials

Your specialist's letter should include:

  • Confirmed LAL-D diagnosis with test results
  • Clinical manifestations showing disease severity
  • Treatment history (supportive care, lipid-lowering therapy outcomes)
  • Kanuma rationale citing FDA labeling and clinical guidelines
  • Monitoring plan for treatment response assessment

Appeals Process in Illinois

Illinois residents have robust appeal rights through both federal Medicare processes and state insurance protections.

Internal Humana Appeals

  • Timeline: File within 65 days of denial
  • Process: Submit written appeal with additional evidence
  • Decision timeframe:
    • Part D drug appeals: 7 days standard, 72 hours expedited
    • Part C medical appeals: 30 days pre-service, 60 days post-service

Independent External Review

After Humana upholds a denial, Illinois law provides additional protection through the Health Carrier External Review Act:

  • Filing deadline: 30 days from final internal denial (shorter than many states)
  • Process: Independent Review Organization (IRO) with board-certified physician reviewer
  • Timeline: Decision within 5 business days of receiving all materials
  • Cost: Free to consumers (insurers pay IRO fees)
  • Binding: IRO decision compels coverage if overturned
Illinois-Specific: The 30-day external review deadline is stricter than the 4-month window in many states—act promptly after internal appeal denial.

Medicare Appeal Levels

For Medicare Advantage members, additional federal appeal levels include:

  1. Level 2: Qualified Independent Contractor (QIC) reconsideration (60 days)
  2. Level 3: Administrative Law Judge hearing (minimum $190 controversy amount for 2025)
  3. Level 4: Medicare Appeals Council review
  4. Level 5: Federal District Court (minimum ~$1,840 controversy amount)

Required Documentation Checklist

Before Starting PA Process

  • Insurance card and member ID
  • Complete LAL enzyme activity test results
  • LIPA genetic testing report (if available)
  • Recent laboratory results (ALT, AST, lipid panel)
  • Hepatic imaging or biopsy results
  • Growth charts (for pediatric patients)
  • Prior treatment records (diet, lipid-lowering medications)
  • Specialist consultation notes

For Appeals

  • Original denial letter
  • All medical records supporting diagnosis
  • Peer-reviewed literature supporting treatment
  • Updated clinical status documentation
  • Specialist letter addressing denial reasons

Cost Considerations

Kanuma is extremely expensive, with costs ranging from approximately $0.89M to $4.9M annually depending on patient weight and dosing requirements. Even with insurance coverage, patients may face significant cost-sharing.

Financial Assistance Options

  • Alexion Access Navigator: Manufacturer support program for coverage assistance
  • Copay assistance: May be available for eligible patients
  • State programs: Illinois residents may qualify for additional assistance through state insurance programs
Note: Medicare patients are generally ineligible for manufacturer copay cards, but may qualify for other support programs.

When to Escalate

Contact Illinois regulators if you encounter coverage problems:

Illinois Department of Insurance

  • Consumer Hotline: 877-527-9431
  • Online complaints: Available through IDOI website
  • Services: Help with appeals, external review applications, insurer compliance issues

Illinois Attorney General Health Care Bureau

  • Health Care Helpline: 1-877-305-5145
  • Services: Informal intervention with insurers, consumer assistance

Counterforce Health specializes in turning insurance denials into successful appeals for complex medications like Kanuma. Our platform analyzes denial letters, identifies specific coverage criteria, and drafts evidence-backed appeals that address each payer requirement systematically. We help patients and clinicians navigate the prior authorization maze by providing targeted documentation strategies that improve approval odds.

FAQ

How long does Humana's prior authorization take for Kanuma in Illinois? Standard decisions within 72 hours; expedited reviews within 24 hours for urgent cases. Complete documentation prevents delays.

What if Kanuma isn't on my Humana formulary? File a formulary exception request citing LAL-D as a rare, life-threatening condition with no therapeutic alternatives.

Can I request an expedited appeal? Yes, if treatment delay could seriously jeopardize your health. Document urgent medical need, especially for infantile-onset LAL-D.

Does step therapy apply to Kanuma? Typically waived since Kanuma is the only FDA-approved LAL-D treatment. Request step therapy exception if required.

What happens if my appeal is denied? Illinois residents can request external review within 30 days through the state insurance department—this provides independent physician review.

How often does Humana require reauthorization? Typically every 6-12 months with updated labs and clinical notes demonstrating ongoing medical necessity and treatment response.

Can I use any infusion center? Humana may restrict to in-network specialty pharmacies and preferred infusion sites. Check your plan's provider network.

What if I move from another state to Illinois? Document any prior Kanuma treatment and response. Illinois coverage criteria may differ from your previous state's requirements.

This guide is for informational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan details. For personalized assistance with your specific situation, consult your healthcare provider and insurance plan directly.

Illinois Resources:

At Counterforce Health, we understand that navigating insurance approvals for rare disease treatments can be overwhelming. Our evidence-based appeal platform helps clinicians and patients build stronger cases for coverage by systematically addressing each payer's specific requirements and denial reasons.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.